274 related articles for article (PubMed ID: 17530673)
1. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
Rahme E; Barkun AN; Toubouti Y; Scalera A; Rochon S; Lelorier J
Arthritis Rheum; 2007 Jun; 57(5):748-55. PubMed ID: 17530673
[TBL] [Abstract][Full Text] [Related]
2. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
3. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.
Rahme E; Barkun A; Nedjar H; Gaugris S; Watson D
Am J Gastroenterol; 2008 Apr; 103(4):872-82. PubMed ID: 18371130
[TBL] [Abstract][Full Text] [Related]
4. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
5. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
6. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
Chen JT; Pucino F; Resman-Targoff BH
J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
[TBL] [Abstract][Full Text] [Related]
8. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
10. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM; Chiou CF; Ofman JJ
Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.
Cheetham TC; Levy G; Niu F; Bixler F
Ann Pharmacother; 2009 Nov; 43(11):1765-73. PubMed ID: 19809010
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
13. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
16. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.
Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S
Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799
[TBL] [Abstract][Full Text] [Related]
17. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors.
Battistella M; Mamdami MM; Juurlink DN; Rabeneck L; Laupacis A
Arch Intern Med; 2005 Jan; 165(2):189-92. PubMed ID: 15668365
[TBL] [Abstract][Full Text] [Related]
18. New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study.
Wang J; Mullins CD; Mamdani M; Rublee DA; Shaya FT
Ann Pharmacother; 2007 Jun; 41(6):937-43. PubMed ID: 17488830
[TBL] [Abstract][Full Text] [Related]
19. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
Rahme E; Pettitt D; LeLorier J
Arthritis Rheum; 2002 Nov; 46(11):3046-54. PubMed ID: 12428249
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Goldstein JL; Cryer B; Amer F; Hunt B
Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
